Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Heart failure reaches 1.5 million people in France and is responsible for 200,000 hospitalizations per year.
Over the past ten years, new therapies have emerged (treatment of martial deficiency, Entresto, iSGLT2).
Hospitalization in a context of acute heart failure is a moment of choice in the history of the disease to introduce recommended treatments under closer supervision (clinical, biological) than in ambulatory, and allows a decrease in hospitalizations, morbidity and mortality.
The purpose of this study is to describe the introduction of heart failure drugs (including iSGLT2) in real-life settings in patients hospitalized for decompensated heart failure.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hospitalized patient for decompensated heart failure | Other | Describe the evolution of heart failure medications during hospitalization for decompensated heart failure. |
| Measure | Description | Time Frame |
|---|---|---|
| Prescription score | Prescription score, ranging from 0 to 10, each type of heart failure treatment (IEC/ARA2, Sacubitril, betablockers, SGLT2i, MRA) being evaluated on a scale of 2. | During hospitalisation for decompensated heart failure (up to 10 days) |
| Measure | Description | Time Frame |
|---|---|---|
| serum concentration of creatinine | Creatinine measured at admission and discharge | During hospitalisation for decompensated heart failure (up to10 days) |
| serum concentration of potassium | Potassium measured at admission and discharge |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Hospitalized (≥24h) patient for decompensated heart failure in cardiology between november 2021 and october 2022
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicolas GIRERD, MD-PhD | CHRU de NANCY | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chr Metz Thionville | Ars-Laquenexy | 57530 | France | |||
| CHRU de NANCY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| During hospitalisation for decompensated heart failure (up to 10 days) |
| Concentration of hemoglobin | hemoglobin measured at admission and discharge | During hospitalisation for decompensated heart failure (up to 10 days) |
| All cause Death | 6 months |
| Rate of hospitalization for heart failure | 6 months |
| Vandœuvre-lès-Nancy |
| 54500 |
| France |